Evaluation of a novel point-of-care enoxaparin monitor with central laboratory anti-Xa levels
Jacqueline Saw(University of British Columbia), David J. Moliterno(University of Kentucky), Kenneth W. Mahaffey(Cardiovascular Institute of the South), Bruce N. Brent(California Pacific Medical Center), Glenn N. Levine(American College of Cardiology), Bruce R. Brodie(European Society of Cardiology), Dean J. Kereiakes(Health Net), Robert J. Applegate(Wake Forest University), Gregory A. Braden(Wake Forest University), J. B. Groce(Moses H Cone Memorial Hospital), Fred Leya(Boston University)
Cited by 15
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k